What You Should Know:
- Today, Sema4 (Nasdaq: SMFR), a health intelligence company, announced it has signed a definitive agreement to acquire GeneDx, a leader in genomic testing and analysis, at a purchase price representing approximately $623 million, strengthening its market-leading health intelligence and genomic screening offerings.
- The combined company is projected to deliver $350 million in pro forma 2022 revenue. In connection with the acquisition,
Read More
Digital Health | News, Analysis, Insights - HIT Consultant
Clarius Launches 10 New Ultrasound Scanners for Apple and Android Devices
What You Should Know:
- Miniaturized to the size of an iPhone, Clarius Mobile Health launches a third-generation product line of high-performance handheld wireless ultrasound scanners for all medical specialists.
- The entire Clarius HD3 line of ultra-portable scanners is built with the latest antenna technology for steadfast connectivity operating on both iOS and Android devices. Octal beamforming technology delivers up to eight times faster frame rates and micron-level resolution
Read More
Jumpstart Health Launches $55M Venture Fund for Black Founded Health Startups
What You Should Know:
- Jumpstart Health Investors, announced this week the launch of Jumpstart Nova, the first venture fund to invest in Black founded and led healthcare innovation companies.
- The $55M fund will invest exclusively in Black founder-led healthcare companies across health IT, digital health, tech-enabled services, diagnostic devices, biotech, medical device manufacturing and consumer health and wellness.
Why It Matters
Marcus Whitney, a leader in healthcare innovation
Read More
Decentralized Clinical Trials Can Achieve Net Financial Benefits of 5X to 14X
What You Should Know:
- New data from Tufts and Medable reveal on average, decentralized clinical trials (DCTs) are associated with reduced clinical trial timelines and can achieve net financial benefits ranging from five to 14 times for Phase II and Phase III trials, respectively.
- The findings are based on financial modeling and analysis of trial data from the Tufts Center for the Study of Drug Development (CSDD), Tufts University School of Medicine, and more than 150 clinical trials
Read More
GSK Launches Accelerated Clinical Trial with Tempus
What You Should Know:
- Tempus and GlaxoSmithKline (GSK) announced an accelerated phase II study evaluating the efficacy and safety of niraparib, an oral, once daily PARP inhibitor, for patients with breast and pancreatic cancers. The study, titled “Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors” (the PAVO study, NCT05169437) is sponsored by Tempus and opened for enrollment on January 7, 2022.
- This trial’s data-driven design and site selection
Read More
Sanofi Taps BrightInsight for Development of Software as a Medical Device
What You Should Know:
- Sanofi, a global biopharmaceutical company focused on human health has inked a strategic partnership with BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solution to bring to market a next-generation digital companion application for one of Sanofi’s products.
- The BrightInsight® Platform has been selected to serve as the underlying infrastructure to accelerate continuous development of one of Sanofi’s
Read More
Chronus Health Raises $22M for Portable, Rapid Blood Analyzer Technology
What You Should Know:
- Chronus Health, a point-of-care diagnostics company raises $22M in Series A funding led by Tarsadia Investments with participation from Monta Vista Capital, SOSV, Savantus Ventures, and an undisclosed strategic investor.
- Chronus intends to use the proceeds of the Series A financing to scale its research, engineering, and data science teams, in addition to accelerating the company’s product and technology development.
Diagnostics on Demand. Reimagined
While
Read More
GrayMatters Health Raises $10M for Biomarker-Based PTSD Therapeutics
What You Should Know:
- GrayMatters Health (GMH), a company set to change the standards of mental health care with biomarker-based therapeutics, beginning with PTSD raises $10 million in Series A funding round led by Otsuka Medical Devices Co., Ltd., bringing total funding to $13.5 million. Additional investors in the Series A round included Joy Ventures, J-Ventures, and J-Impact. Existing GMH investors, Marius Nacht and Joyance Ventures, also
Read More
Headspace Acquires AI Mental Health Startup Sayana
What You Should Know:
- Headspace Health, today announced the acquisition of Sayana, an AI-driven mental health and wellness company. With this acquisition, Headspace Health is expanding its ability to provide highly-personalized mental health care and content to its millions of users in 190+ countries.
- The acquisition comes approx. 6 months after the $3B merger of Headspace and Ginger, and will add further AI capabilities to what is the most accessible and comprehensive digital
Read More
First Stop Health Launches Virtual Primary Care for Access to Urgent Care
What You Should Know:
- First Stop Health® (FSH), a virtual care provider in the areas of telemedicine and virtual mental health, today announced the availability of Virtual Primary Care for its clients and members throughout the U.S.
- Virtual Primary Care gives members convenient, fast and affordable access to high-quality care while helping to lower healthcare costs for employers.
How FSH Virtual Primary Care Features
FSH Virtual Primary Care is available via app, website or
Read More
